Bioreactor technologies to support liver function in vitro

Mohammad Ebrahimkhani, Jaclyn A Shepard Neiman, Micha Sam B Raredon, David J. Hughes, Linda G. Griffith

Research output: Contribution to journalReview article

77 Citations (Scopus)

Abstract

Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from prediction of metabolism and toxicity of small molecule drugs, to understanding off-target effects of proteins, nucleic acid therapies, and targeted therapeutics, to serving as disease models for drug development. Here we provide perspective on the evolving landscape of bioreactor-based models to meet old and new challenges in drug discovery and development, emphasizing design challenges in maintaining long-term liver-specific function and how emerging technologies in biomaterials and microdevices are providing new experimental models.

Original languageEnglish (US)
Pages (from-to)132-157
Number of pages26
JournalAdvanced Drug Delivery Reviews
Volume69-70
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Bioreactors
Technology
Liver
Biocompatible Materials
Drug Discovery
Therapeutics
Human Body
Pharmaceutical Preparations
Nucleic Acids
Homeostasis
Theoretical Models
In Vitro Techniques
Proteins

Keywords

  • Bioreactor
  • Drug development
  • Drug toxicity
  • Hepatocytes
  • Liver non-parenchymal cells
  • Microfluidic
  • Organ on chip
  • Tissue engineering

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Medicine(all)

Cite this

Ebrahimkhani, M., Neiman, J. A. S., Raredon, M. S. B., Hughes, D. J., & Griffith, L. G. (2014). Bioreactor technologies to support liver function in vitro. Advanced Drug Delivery Reviews, 69-70, 132-157. https://doi.org/10.1016/j.addr.2014.02.011

Bioreactor technologies to support liver function in vitro. / Ebrahimkhani, Mohammad; Neiman, Jaclyn A Shepard; Raredon, Micha Sam B; Hughes, David J.; Griffith, Linda G.

In: Advanced Drug Delivery Reviews, Vol. 69-70, 2014, p. 132-157.

Research output: Contribution to journalReview article

Ebrahimkhani, M, Neiman, JAS, Raredon, MSB, Hughes, DJ & Griffith, LG 2014, 'Bioreactor technologies to support liver function in vitro', Advanced Drug Delivery Reviews, vol. 69-70, pp. 132-157. https://doi.org/10.1016/j.addr.2014.02.011
Ebrahimkhani M, Neiman JAS, Raredon MSB, Hughes DJ, Griffith LG. Bioreactor technologies to support liver function in vitro. Advanced Drug Delivery Reviews. 2014;69-70:132-157. https://doi.org/10.1016/j.addr.2014.02.011
Ebrahimkhani, Mohammad ; Neiman, Jaclyn A Shepard ; Raredon, Micha Sam B ; Hughes, David J. ; Griffith, Linda G. / Bioreactor technologies to support liver function in vitro. In: Advanced Drug Delivery Reviews. 2014 ; Vol. 69-70. pp. 132-157.
@article{b8b6519c344d48ee81e47c2d173885ee,
title = "Bioreactor technologies to support liver function in vitro",
abstract = "Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from prediction of metabolism and toxicity of small molecule drugs, to understanding off-target effects of proteins, nucleic acid therapies, and targeted therapeutics, to serving as disease models for drug development. Here we provide perspective on the evolving landscape of bioreactor-based models to meet old and new challenges in drug discovery and development, emphasizing design challenges in maintaining long-term liver-specific function and how emerging technologies in biomaterials and microdevices are providing new experimental models.",
keywords = "Bioreactor, Drug development, Drug toxicity, Hepatocytes, Liver non-parenchymal cells, Microfluidic, Organ on chip, Tissue engineering",
author = "Mohammad Ebrahimkhani and Neiman, {Jaclyn A Shepard} and Raredon, {Micha Sam B} and Hughes, {David J.} and Griffith, {Linda G.}",
year = "2014",
doi = "10.1016/j.addr.2014.02.011",
language = "English (US)",
volume = "69-70",
pages = "132--157",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Bioreactor technologies to support liver function in vitro

AU - Ebrahimkhani, Mohammad

AU - Neiman, Jaclyn A Shepard

AU - Raredon, Micha Sam B

AU - Hughes, David J.

AU - Griffith, Linda G.

PY - 2014

Y1 - 2014

N2 - Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from prediction of metabolism and toxicity of small molecule drugs, to understanding off-target effects of proteins, nucleic acid therapies, and targeted therapeutics, to serving as disease models for drug development. Here we provide perspective on the evolving landscape of bioreactor-based models to meet old and new challenges in drug discovery and development, emphasizing design challenges in maintaining long-term liver-specific function and how emerging technologies in biomaterials and microdevices are providing new experimental models.

AB - Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from prediction of metabolism and toxicity of small molecule drugs, to understanding off-target effects of proteins, nucleic acid therapies, and targeted therapeutics, to serving as disease models for drug development. Here we provide perspective on the evolving landscape of bioreactor-based models to meet old and new challenges in drug discovery and development, emphasizing design challenges in maintaining long-term liver-specific function and how emerging technologies in biomaterials and microdevices are providing new experimental models.

KW - Bioreactor

KW - Drug development

KW - Drug toxicity

KW - Hepatocytes

KW - Liver non-parenchymal cells

KW - Microfluidic

KW - Organ on chip

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=84899986727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899986727&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2014.02.011

DO - 10.1016/j.addr.2014.02.011

M3 - Review article

C2 - 24607703

AN - SCOPUS:84899986727

VL - 69-70

SP - 132

EP - 157

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -